Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Warren Moore

Nuclear Medicine Houston, TX Medical Doctor

NPI 1174525034 CMS profile 189741

6720 Bertner St, Mc3 261, Houston, TX 77030

Open in the dashboard

General payments

$13,114

27 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Warren Moore of Houston, TX is reported in the CMS Open Payments database as having received $13,114 across 27 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nuclear Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $31 1
2022 General $3,168 3
2021 General $128 5
2020 General $3,180 9
2019 General $6,607 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Warren Moore
  • Nuclear Medicine median
  • Middle half of Nuclear Medicine
  • National median

In program year 2025, general payments to Warren Moore were reported at $0. Among 197 Nuclear Medicine profiles paid that year, the median was $146 and the middle half received between $40 and $372.

Show as a table
Year Warren Moore Nuclear Medicine median Middle half National median
2019 $6,607 $125 $54–$531 $163
2020 $3,180 $99 $34–$2,125 $114
2021 $128 $96 $22–$874 $132
2022 $3,168 $102 $38–$240 $149
2023 $31 $123 $51–$257 $160
2024 $0 $121 $51–$390 $164
2025 $0 $146 $40–$372 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Astellas Pharma US Inc $12,678 11 payments
  2. Boston Scientific Corporation $278 11 payments
  3. Biocompatibles, Inc. $61 3 payments
  4. Ge Healthcare $56 1 payment
  5. Astellas Pharma Global Development $42 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,040 4 payments
  2. Food and Beverage $732 18 payments
  3. Education $221 3 payments
  4. Travel and Lodging $121 2 payments
Products named General payments · program years 2019–2023
  1. TheraSphere Y90 Glass Microspheres 10 GBq $119 3 payments
  2. THERASPHERE TheraSphere $69 3 payments
  3. THERASPHERE-BIO $61 3 payments
  4. LEXISCAN $42 1 payment
  5. GENERAL - EMBOLICS $35 2 payments
  6. LC BEAD $20 1 payment
  7. THERASPHERE Pain Management $17 1 payment
  8. THERASPHERE Embolics $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$11,316

Medicare's payments for the services billed

Medicare patients

273

Average age 72

Services billed

283

136 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 56%
Ischemic heart disease 53%
Arthritis 49%
Diabetes 46%
Heart failure 45%
Atrial fibrillation 33%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nuclear Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record